A Comparison of Efficacy and Safety During Endoscopic Submucosal Dissection Between Dexmedetomidine-remifentanil and Propofol-remifentanil

• Status: Completed
• Trial end date: 2013-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Adequate, safe sedation is essential for Endoscopic submucosal dissection. Dexmedetomidine is a potent and selective a2-adrenoceptor agonist used for sedative and analgesic effects, but it is limited to use alone. The investigators designed this study to compare the effect and safety of two sedatives, dexmedetomidine and propofol in Endoscopic Submucosal Dissection (ESD), when sufficient analgesia-remifentanil is administered all throughout the procedure.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yonsei University
• Treatments: Dexmedetomidine; Propofol; Remifentanil

Criteria

Inclusion Criteria:

• Age ≥20

• American Society of Anaesthesiologists(ASA) physical status classification I~III

• Early gastric cancer patients who were scheduled for Endoscopic submucosal dissection

Exclusion Criteria:

• Age < 20

• American Society of Anaesthesiologists(ASA) physical status classification IV

• those with end-organ diseases (i.e. heart failure, respiratory failure, hepatic failure, renal failure)

• known drug allergies or history of drug abuse

• psychological disease